DMDavid P. Maison

David P. Maison

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David P. Maison has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • Vivek Ramchandra Nerurkar

    Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA

    4 shared publications
  • Sean B. Cleveland

    Information Technology Services - Cyberinfrastructure, University of Hawaii - System, USA

    3 shared publications
  • Timothy J. Henrich

    Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA

    3 shared publications
  • Cecilia M. Shikuma

    Department of Tropical Medicine, Medical Microbiology, and Pharmacology, University of Hawaiʻi at Mānoa, Honolulu, Hawaii 96813

    2 shared publications
  • Lauren L. Ching

    Department of Tropical Medicine, Medical Microbiology, and Pharmacology, University of Hawaiʻi at Mānoa, Honolulu, Hawaii 96813

    2 shared publications
  • Mariana Gerschenson

    Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, United States

    2 shared publications

Latest Publications

  • Open Access

    Multiomic and Spatial Profiling of Colorectal Tissue Reveals Viral Persistence and Immune Dysregulation in Long COVID

    by Brian LaFranchi, David P. Maison, Joanna Vinden, Antonio E. Rodriguez, Ali Tout, Lilian Grimbert, Emanuel Velazquez, Urmila Vudali, Belen Altamirano Poblano, Thomas Dalhuisen, et al.

    Long COVID (LC) – a chronic condition characterized by persistent, debilitating symptoms following SARS-CoV-2 infection – has emerged as a major public health challenge. Although many interrelated mechanisms have been proposed as drivers of LC, the root causes have yet to be identified, posing significant challenges for therapeutic development. While many blood-based studies have been conducted, they have not yielded conclusive mechanistic insights into LC pathogenesis. Attention has therefore turned toward direct tissue investigation, with the gastrointestinal (GI) tract becoming a major focus due to evidence that virus or viral components can persist at this site for months to years following an episode of COVID-19. Here, we performed a high-dimensional characterization of colorectal tissue and peripheral blood in a highly characterized cohort of 44 people with LC and 13 recovered controls. We profiled SARS-CoV-2 persistence, host immune responses, and tissue inflammation using bulk and single-cell RNA sequencing, nCounter RNA probe hybridization, quantitative PCR, metagenomic next-generation sequencing, plasma proteomics, high-dimensional spectral flow cytometry, in situ-hybridization/immunohistochemistry, and single-cell digital spatial omics. Our results support a model in which LC is driven by long-term immune dysregulation and perturbations of the regulatory gut immune environment which imply ongoing viral persistence, although direct viral detection was only observed in a subset of participants. Specifically, we identify a tissue-based transcriptional environment in which SARS-CoV-2 activates innate myeloid immune signaling, driving chronic inflammation while simultaneously downregulating pathways responsible for immune-mediated clearance of infected cells, including antigen presentation, phagocytosis, cytotoxic immune cell trafficking, and granzyme production. Importantly, signatures in peripheral blood are considerably weaker than those observed in tissue. Together, these findings provide a direct biological rationale for therapeutic strategies in LC aimed at enhancing or redirecting cytotoxic immune function to overcome immune dysregulation and clear persistent viral reservoirs.


  • Open Access

    Peripheral immune progression to long COVID is associated with mitochondrial gene transcription: A meta-analysis

    by David P. Maison, Vedbar S. Khadka, Isam Mohd-Ibrahim, Michael J. Peluso, Timothy J. Henrich, Youping Deng, Mariana Gerschenson


  • Top Cited Papers
    Open Access

    COVID-19 clinical presentation, management, and epidemiology: a concise compendium

    by David P. Maison, Hawi Tasissa, Amelia Deitchman, Michael J. Peluso, Youping Deng, F. DeWolfe Miller, Timothy J. Henrich, Mariana Gerschenson

    Coronavirus Disease 2019, caused by severe acute respiratory coronavirus 2, has been an ever-evolving disease and pandemic, profoundly impacting clinical care, drug treatments, and understanding. In response to this global health crisis, there has been an unprecedented increase in research exploring new and repurposed drugs and advancing available clinical interventions and treatments. Given the widespread interest in this topic, this review aims to provide a current summary—for interested professionals not specializing in COVID-19—of the clinical characteristics, recommended treatments, vaccines, prevention strategies, and epidemiology of COVID-19. The review also offers a historical perspective on the pandemic to enhance understanding.


  • The promise and reality of new immune profiling technologies

    by Sara Suliman, David P. Maison, Timothy J. Henrich


  • Open Access

    Altered mitochondrial respiration in peripheral blood mononuclear cells of post-acute sequelae of SARS-CoV-2 infection

    by Sahera Dirajlal-Fargo, David P Maison, Jared C Durieux, Anastasia Andrukhiv, Nicholas Funderburg, Kate Ailstock, Mariana Gerschenson, Grace A Mccomsey


  • Open Access

    SARS-CoV-2 and the host-immune response

    by David P. Maison, Youping Deng, Mariana Gerschenson

    The SARS-CoV-2 pandemic and the COVID-19 disease have affected everyone globally, leading to one of recorded history’s most significant research surges. As our knowledge evolves, our approaches to the virus and treatments must also evolve. The evaluation of future research approaches to SARS-CoV-2 will necessitate reviewing the host immune response and viral antagonism of that response. This review provides an overview of the current knowledge on SARS-CoV-2 by summarizing the virus and human response. The focuses are on the viral genome, replication cycle, host immune activation, response, signaling, and antagonism. To effectively fight the pandemic, efforts must focus on the current state of research to help develop treatments and prepare for future outbreaks.


  • Open Access

    Genomic analysis of SARS-CoV-2 variants of concern circulating in Hawai’i to facilitate public-health policies

    by David P. Maison, Sean B. Cleveland, Vivek R. Nerurkar

    Using genomics, bioinformatics and statistics, herein we demonstrate the effect of statewide and nationwide quarantine on the introduction of SARS-CoV-2 variants of concern (VOC) in Hawai’i. To define the origins of introduced VOC, we analyzed 260 VOC sequences from Hawai’i, and 301,646 VOC sequences worldwide, deposited in the GenBank and global initiative on sharing all influenza data (GISAID), and constructed phylogenetic trees. The trees define the most recent common ancestor as the origin. Further, the multiple sequence alignment used to generate the phylogenetic trees identified the consensus single nucleotide polymorphisms in the VOC genomes. These consensus sequences allow for VOC comparison and identification of mutations of interest in relation to viral immune evasion and host immune activation. Of note is the P71L substitution within the E protein, the protein sensed by TLR2 to produce cytokines, found in the B.1.351 VOC may diminish the efficacy of some vaccines. Based on the phylogenetic trees, the B.1.1.7, B.1.351, B.1.427, and B.1.429 VOC have been introduced in Hawai’i multiple times since December 2020 from several definable geographic regions. From the first worldwide report of VOC in GenBank and GISAID, to the first arrival of VOC in Hawai’i, averages 320 days with quarantine, and 132 days without quarantine. As such, the effect of quarantine is shown to significantly affect the time to arrival of VOC in Hawai’i. Further, the collective 2020 quarantine of 43-states in the United States demonstrates a profound impact in delaying the arrival of VOC in states that did not practice quarantine, such as Utah. Our data demonstrates that at least 76% of all definable SARS-CoV-2 VOC have entered Hawai’i from California, with the B.1.351 variant in Hawai’i originating exclusively from the United Kingdom. These data provide a foundation for policy-makers and public-health officials to apply precision public health genomics to real-world policies such as mandatory screening and quarantine.


  • Open Access

    Algorithm for the Quantitation of Variants of Concern for Rationally Designed Vaccines Based on the Isolation of SARS-CoV-2 Hawaiʻi Lineage B.1.243

    by David P. Maison, Lauren L. Ching, Sean B. Cleveland, Alanna C. Tseng, Eileen Nakano, Cecilia M. Shikuma, Vivek R. Nerurkar

    SARS-CoV-2 worldwide emergence and evolution has resulted in variants containing mutations resulting in immune evasive epitopes that decrease vaccine efficacy. We acquired clinical samples, analyzed SARS-CoV-2 genomes, used the most worldwide emerged spike mutations from Variants of Concern/Interest, and developed an algorithm for monitoring the SARS-CoV-2 vaccine platform. The algorithm partitions logarithmic-transformed prevalence data monthly and Pearson’s correlation determines exponential emergence. The SARS-CoV-2 genome evaluation indicated 49 mutations. Nine of the ten most worldwide prevalent (>70%) spike protein changes have r- values >0.9. The tenth, D614G, has a prevalence >99% and r -value of 0.67. The resulting algorithm is based on the patterns these ten substitutions elucidated. The strong positive correlation of the emerged spike protein changes and algorithmic predictive value can be harnessed in designing vaccines with relevant immunogenic epitopes. SARS-CoV-2 is predicted to remain endemic and continues to evolve, so must SARS-CoV-2 monitoring and next-generation vaccine design.